pasireotide pamoate - Profile

What are the generic sources for pasireotide pamoate and what is the scope of freedom to operate?

Pasireotide pamoate is the generic ingredient in one branded drug marketed by Recordati Rare and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pasireotide pamoate has one hundred and thirty-five patent family members in fifty-three countries.

Summary for pasireotide pamoate

International Patents:	135
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for pasireotide pamoate

Constraining patent/regulatory exclusivity:

9,351,923

Dosage:

FOR SUSPENSION;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for pasireotide pamoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-004	Jun 29, 2018		RX	Yes	No	7,473,761		Y	Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-004	Jun 29, 2018		RX	Yes	No	7,759,308		Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-004	Jun 29, 2018		RX	Yes	No	9,351,923		Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-001	Dec 15, 2014		RX	Yes	No	7,759,308		Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-001	Dec 15, 2014		RX	Yes	No	9,351,923		Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-001	Dec 15, 2014		RX	Yes	No	7,473,761		Y	Y
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-005	Jun 29, 2018		RX	Yes	No	7,473,761		Y	Y

Expired US Patents for pasireotide pamoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-002	Dec 15, 2014	6,225,284
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-001	Dec 15, 2014	6,225,284
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-003	Dec 15, 2014	6,225,284
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-002	Dec 15, 2014	8,822,637
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-003	Dec 15, 2014	8,822,637
Recordati Rare	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-001	Dec 15, 2014	8,822,637

International Patents for pasireotide pamoate

Country	Patent Number	Title	Estimated Expiration
Luxembourg	92024
Australia	2004289055	Microparticles comprising somatostatin analogues
Tunisia	SN06136	MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES
Tunisia	2009000447	AN EXTENTED-RELEASE COMPOSITION COMPRISING A SOMATOSTATIN DERIVATIVE IN MICROPARTICLES
Uruguay	31103	COMPOSICIONES FARMACEUTICAS EN BASE A MICROPARTICULAS COMPRENDIENDO UN ANALOGO DE SOMATOSTATINA, PROCESO DE PREPARACION Y APLICACIONES
World Intellectual Property Organization (WIPO)	0210192
Peru	20090387	FORMULACION DE PASIREOTIDA

Supplementary Protection Certificates for pasireotide pamoate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1307486	C 2012 018	Romania		PRODUCT NAME: PASIREOTIDA SI SARURILE ACCEPTABILE FARMACEUTIC ALEACESTEIACICLO[(4R)-4-(2-AMINOETILCARBAMOILOXI)-L-PROLIL-L-FENILGLICIL-D-TRIPTOFIL-L-LISIL-4-O-BENZIL-L-TIROSIL-L-FENILALANIL-); NATIONAL AUTHORISATION NUMBER: RO EU/1/12/753/001 - RO EU/1/12/753/012; DATE OF NATIONAL AUTHORISATION: 20120424; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/12/753/001 - EMEA EU/1/12/753/012; DATE OF FIRST AUTHORISATION IN EEA: 20120424
1307486	418	Finland
1307486	CA 2012 00024	Denmark
1307486	C300536	Netherlands		PRODUCT NAME: PASIREOTIDE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER PASIREOTIDEDI-ASPARTAAT; REGISTRATION NO/DATE: EU/1/12/753/001-012 20120424
1686964	300716	Netherlands		PRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119
1686964	CR 2015 00026	Denmark		PRODUCT NAME: PASIREOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET HVILKET SOM HELST HYDRAT DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753, C(2014)8916 20141121
1307486	2012/027	Ireland		PRODUCT NAME: PASIREOTIDE OR A SALT OR COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/12/753/001-EU/1/12/753/012 20120424

Summary

Last updated: February 3, 2026

Pasireotide pamoate, marketed as Signifor LAR, is a long-acting somatostatin analog primarily used in the treatment of acromegaly and Cushing’s disease. This report evaluates the current investment landscape, market dynamics, and projected financial trajectories, addressing key industry factors, competitive positioning, regulatory environment, and commercialization potential. The analysis underscores strengths, challenges, and strategic considerations pertinent to stakeholders seeking to assess investment viability.

What Is the Investment Scenario for Pasireotide Pamoate?

Market Size and Growth Potential

Metric	Figures	Source/Notes
Global acromegaly market (2022)	USD 290 million	[1]
Global Cushing’s syndrome market (2022)	USD 120 million	[2]
CAGR (2022–2027)	4.8% (acromegaly), 3.9% (Cushing’s)	[1][2]
Forecasted global sales (2027)	USD 410 million (acromegaly), USD 155 million (Cushing’s)	Estimated based on CAGR

The total addressable market (TAM) for pasireotide pamoate approximates USD 410 million in acromegaly and USD 155 million in Cushing’s disease by 2027, with incremental growth driven by increased diagnosis, expanded treatment indications, and adoption of long-acting formulations.

Investment Drivers

• Therapeutic Differentiation: Long-acting formulation improved adherence compared to daily injections of octreotide or lanreotide.
• Regulatory Approvals: FDA approval for acromegaly (2014) and extended approval for Cushing’s (2017) expands market access.
• Pipeline Development: Trials exploring efficacy in neuroendocrine tumors and other hormonal conditions may broaden indications.
• Market Penetration Strategies: Strategic partnerships, competitive pricing, and targeted marketing influence uptake.

Investment Risks

• Market Penetration Challenges: Established competition from octreotide and lanreotide, with generics reducing pricing power.
• Pricing and Reimbursement Policies: Variability across geographies impacts revenue potential.
• Regulatory Uncertainties: Post-market surveillance and approval extensions require ongoing compliance.
• Manufacturing Capabilities: Complexity in long-acting injectable formulations necessitates scalable production.

How Do Market Dynamics Impact Pasireotide Pamoate?

Competitive Landscape

Competitors	Key Products	Market Share (Estimated)	Strengths	Limitations
Novartis	Sandostatin LAR (octreotide)	>60%	Established: extensive data, broad indication	Higher frequency dosing, injection site reactions
Ipsen	Somatuline Depot (lanreotide)	~25%	Longer dosing intervals, widespread use	Similar efficacy, less differentiation
Recordati	Pasireotide (Signifor)	Remaining	Unique receptor affinity, approved for both indications	Higher cost, injection site discomfort, limited penetration

The competitive environment favors well-established products, but pasireotide's unique receptor activity offers a mechanistic edge, potentially advantageous for niche markets.

Regulatory Environment and Policy Influences

• FDA Approval: 2014 for acromegaly; 2017 for Cushing’s. Approval extensions pending for new indications.
• EMA Approvals: Similar timelines, with regional variations.
• Pricing and Reimbursement: Governed by country-specific policies; aggressive negotiations can restrict margins.

Market Access and Reimbursement

Region	Reimbursement Level	Market Access Challenges	Notes
North America	High	Payer negotiations	Competitive with generics
Europe	Varies	Reimbursement thresholds	Favorable in selected countries
Asia	Emerging	Approvals pending	Growing opportunity

Manufacturing and Supply Chain Considerations

• Formulation Complexity: Long-acting depot requires specialized manufacturing processes.
• Supply Chain Risks: Key raw materials supply, cold chain logistics.
• Scaling Capabilities: Capable manufacturers are limited, impacting cost and supply security.

What Is the Financial Trajectory for Pasireotide Pamoate?

Revenue Projections and Break-Even Analysis

Year	Estimated Global Sales (USD millions)	Assumptions	Key Growth Drivers
2023	120	Initial market penetration	Physician awareness, payer coverage
2024	160	Increased adoption	Expanded indications, pipeline progress
2025	210	Market expansion	Competitive positioning, patient preference
2026	280	Greater market share	New patient segments, biosimilars impact
2027	410	Peak market potential	Broader indications, global reach

Break-even projected by 2024, assuming entry costs and marketing investments are balanced by sales growth.

Cost Structure and Margins

Cost Elements	Estimated % of Revenue	Note
Manufacturing	30%	Dependent on scale efficiency
R&D	10–15%	Ongoing pipeline investments
Commercialization	20–25%	Marketing, sales team expansion
Distribution and Logistics	5–10%	Cold chain management

Gross margins estimated at 60–70%, with net margins improving as market share solidifies.

Funding and Investment Capital Needs

• Upfront Investments: For manufacturing scale-up, clinical trial expansions, and marketing campaigns.
• Potential ROI: ROI timelines aligned with peak sales in 2026–2027, with IRRs estimated at 15–20% contingent on market penetration.

How Do Comparative Market Trajectories and Investment Opportunities Vary?

Aspect	Pasireotide Pamoate	Octreotide/Lanreotide	Key Differences
Market Size	USD 410M (2027)	USD 330M (2022)	Longer-term growth, niche differentiation
Competitive Edge	Longer dosing interval, receptor affinity	Established, competitive pricing	Differentiation could command premium
Regulatory Flexibility	Moderate	Established	Opportunities for new indications
Pricing Power	Moderate	High (for generics)	Premium pricing support with differentiation

Alternatives and Complementary Therapies

• Pegvisomant: GH receptor antagonist used in resistant cases.
• Combination Therapy: Potential for combined use with dopamine agonists or corticotropin-releasing hormone antagonists.

What Are the Key Considerations for Stakeholders?

• Market Penetration Strategies: Collaboration with payers, physicians to overcome resistance from entrenched therapies.
• Pipeline Development: Broadening indications enhances market share and minimizes reliance on monotherapy.
• Pricing Strategies: Balancing between premium positioning and payer affordability.
• Regulatory Engagement: Early and proactive engagement to facilitate approval of new indications.
• Supply Chain Scalability: Ensuring manufacturing aligns with projected growth.

Key Takeaways

• Signifor LAR demonstrates steady growth potential driven by unmatched dosing convenience and receptor selectivity.
• Market size, while niche, is expanding with an expected USD 565 million valuation by 2027, supported by regulatory approvals and increased diagnosis rates.
• Competitive headwinds include entrenched brands, generics, and pricing pressures, requiring differentiated positioning strategies.
• Financial trajectories indicate breakeven as early as 2024 with robust profit potential through 2027, assuming successful market penetration.
• Pipeline expansion into other neuroendocrine disorders can significantly broaden revenue streams.

FAQs

Q1: What are the primary challenges inhibiting market growth for pasireotide pamoate?
A1: Challenges include entrenched competitors, reimbursement constraints, high manufacturing costs, and limited indication expansion pathways.

Q2: How does pasireotide’s receptor affinity influence its therapeutic positioning?
A2: Pasireotide has broader receptor affinity (primarily somatostatin receptor subtypes 1, 2, 3, and 5), offering superior efficacy in certain tumors, which can justify premium pricing and targeted marketing.

Q3: What strategies can enhance market adoption of pasireotide pamoate?
A3: Strategies include developing new indications, optimizing pricing and reimbursement negotiations, clinician education, and expanding global regulatory approvals.

Q4: How does the pipeline influence current investment decisions?
A4: Active pipeline development in neuroendocrine tumors and other hormonal disorders enhances long-term revenue potential, making the asset more attractive for sustained investment.

Q5: What is the likelihood of biosimilar competition impacting pasireotide?
A5: Biosimilar entry is plausible post-patent expiry (potentially past 2030), but current patent protections and manufacturing complexities delay immediate competition.

---

Sources:
[1] IMS Health, "Global Market Insights," 2022.
[2] EvaluatePharma, "Cushing’s Disease Market Analysis," 2022.